DURHAM, N.C. — November 4, 2025 — Leads & Copy — Bioventus Inc. (Nasdaq: BVS) reported its Q3 revenue of $138.7 million was comparable to last year, with organic revenue up 8%. GAAP earnings were $0.05 per diluted share, up from a prior-year loss of $0.08 per diluted share. Non-GAAP earnings rose 200% to $0.15 per diluted share. Cash from operations increased 192% to $30.1 million. The company reaffirmed its 2025 revenue, Adjusted EBITDA, and Non-GAAP EPS guidance.
Rob Claypoole, Bioventus President and CEO, noted the team’s exceptional quarter with above-market organic revenue growth, increased profitability, and significant cash flow acceleration. He said the company is committed to its 2025 goals, strategic growth investments, and enhancing value for customers, patients, and shareholders.
Third-quarter highlights included Pain Treatments revenue of $67.2 million, up 6.4%, and Surgical Solutions revenue of $50.2 million, up 9.3%. Restorative Therapies revenue was $21.3 million. Bioventus launched the XCELL PRP System and initiated a limited launch of StimTrial and TalisMann.
Bioventus reaffirmed its 2025 financial guidance, projecting net sales of $560 million to $570 million, Adjusted EBITDA of $112 million to $116 million, and Non-GAAP EPS of $0.64 to $0.68.
Contact: Dave Crawford, investor.relations@bioventus.com
